ENTRY       D08774            Mixture   Drug
NAME        Amoxicillin hydrate, clarithromycin and lansoprazole;
            Lansap (TN);
            Prevpac (TN)
PRODUCT
  GENERIC   LANSOPRAZOLE, AMOXICILLIN, CLARITHROMYCIN (Rising Pharma Holdings)
COMPONENT   Amoxicillin hydrate [DR:D00229], Clarithromycin [DR:D00276], Lansoprazole [DR:D00355]
CLASS       Metabolizing enzyme substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
              DG01522  CYP3A4 inhibitor
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
REMARK      ATC code: A02BD07 J01RA01
            Product: D08774<US>
EFFICACY    Antibacterial
  DISEASE   Helicobacter pylori infection [DS:H00320]
COMMENT     Lansoprazole is primarily metabolized by CYP2C19 and CYP3A4.
            Clarithromycin is an inhibitor and a substrate of CYP3A4, and it is an inhibitor of P-gp.
METABOLISM  Enzyme: CYP2C19 [HSA:1557], CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP3A4 [HSA:1576]
            Transporter inhibition: ABCB1 [HSA:5243]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A02 DRUGS FOR ACID RELATED DISORDERS
               A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
                A02BD Combinations for eradication of Helicobacter pylori
                 A02BD07 Lansoprazole, amoxicillin and clarithromycin
                  D08774  Amoxicillin hydrate, clarithromycin and lansoprazole &lt;US&gt;
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J01 ANTIBACTERIALS FOR SYSTEMIC USE
               J01R COMBINATIONS OF ANTIBACTERIALS
                J01RA Combinations of antibacterials
                 J01RA01 Penicillins, combinations with other antibacterials
                  D08774  Amoxicillin hydrate, clarithromycin and lansoprazole &lt;US&gt;
            USP drug classification [BR:br08302]
             Gastrointestinal Agents
              Gastrointestinal Agents, Other
               Lansoprazole/ Amoxicillin/ Clarithromycin
                D08774  Amoxicillin hydrate, clarithromycin and lansoprazole
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               D08774  Amoxicillin hydrate, clarithromycin and lansoprazole
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D08774  Amoxicillin hydrate, clarithromycin and lansoprazole
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               DG01522  CYP3A4 inhibitor
                D08774  Amoxicillin hydrate, clarithromycin and lansoprazole
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D08774  Amoxicillin hydrate, clarithromycin and lansoprazole
            Antimicrobials [BR:br08307]
             Antibacterials
              Cell wall biosynthesis inhibitor, beta-lactam
               Extended spectrum penicillin
                D08774  Amoxicillin hydrate, clarithromycin and lansoprazole &lt;US&gt;
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D08774
             Drug transporters
              D08774
DBLINKS     PubChem: 96025457
///
